This episode was recorded before 31 July 2024. Professor Marcus Maurer, Dr Carolina Vera Ayala, and Associate Professor Jonny Peter discuss how new therapeutics progress through the development pipeline, noting the “huge amount of data” required on safety before a molecule enters clinical trials. They also shed light on drug repurposing and why children are a “critical group” for inclusion in trials. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Additional resources for this episode: Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria’ podcast episodes! For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related